265 related articles for article (PubMed ID: 29668469)
1. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
[TBL] [Abstract][Full Text] [Related]
2. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
6. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
7. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
[TBL] [Abstract][Full Text] [Related]
8. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
[TBL] [Abstract][Full Text] [Related]
9. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
[TBL] [Abstract][Full Text] [Related]
10. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
11. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
[TBL] [Abstract][Full Text] [Related]
12. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5.
Nozawa A; Ozeki M; Yasue S; Endo S; Kadowaki T; Ohnishi H; Muramatsu H; Hama A; Takahashi Y; Kojima S; Fukao T
Int J Hematol; 2020 Nov; 112(5):728-733. PubMed ID: 32519173
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes.
Chaubey R; Sazawal S; Dada R; Mahapatra M; Saxena R
Indian J Med Res; 2011 Oct; 134(4):452-7. PubMed ID: 22089606
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
de Lima M; Giralt S; Thall PF; de Padua Silva L; Jones RB; Komanduri K; Braun TM; Nguyen HQ; Champlin R; Garcia-Manero G
Cancer; 2010 Dec; 116(23):5420-31. PubMed ID: 20672358
[TBL] [Abstract][Full Text] [Related]
18. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
20. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
